Actelion & Nippon Shinyaku vs. Cipla: Selexipag Patent Victory Secures Uptravi® IV Market Exclusivity
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Actelion Pharmaceuticals US, Inc. et al. v. Cipla Limited et al. |
| Case Number | 1:23-cv-00389 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Apr 2023 – Aug 2024 (502 days) 1 YEAR 4 MONTHS |
| Outcome | Plaintiff Win — Permanent Injunction |
| Patents at Issue | |
| Accused Products | Cipla’s Generic Selexipag for Injection (Uptravi® IV biosimilar) |
Case Overview
The Parties
⚖️ Plaintiffs
Subsidiaries of Johnson & Johnson’s Janssen Pharmaceutical and holder of commercial rights to Uptravi® (selexipag), with Nippon Shinyaku Co., Ltd. holding foundational patents on selexipag’s crystalline form.
🛡️ Defendants
India-headquartered generic pharmaceutical manufacturer seeking regulatory approval to market a generic version of Uptravi® IV (selexipag for injection).
Patents at Issue
This landmark case involved two U.S. patents covering fundamental pharmaceutical crystalline forms and their applications. Patents of this nature are crucial for extending market exclusivity beyond initial composition-of-matter patent expiration.
- • US 8,791,122 — Directed to the Form-I crystal of selexipag and methods for its production.
- • US 9,284,280 — Directed to the use of the Form-I crystal compound in pharmaceutical applications.
Designing a similar pharmaceutical product?
Check if your API formulation or crystalline form might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Delaware District Court entered a Consent Judgment and Order of Permanent Injunction on August 20, 2024. Cipla is permanently enjoined from making, using, selling, offering for sale, or importing its ANDA product (selexipag for injection 1.8 mg/vial) until the expiration of U.S. Patent Nos. 8,791,122 and 9,284,280, including any applicable patent term extensions and associated exclusivity periods. No monetary damages were disclosed in the public record.
Key Legal Issues
This consent judgment represents a stipulated resolution where Cipla, for purposes of this action, agreed that both patents-in-suit are valid and enforceable. This strategically avoids lengthy litigation and reinforces the enforceability of polymorph patents when a specific crystal form is critical for a pharmaceutical formulation’s stability or bioavailability. This outcome has lasting implications for how pharmaceutical companies defend their formulations and polymorph patents against generic ANDA challengers.
Freedom to Operate (FTO) Analysis for Pharma IP
This case highlights critical IP risks in pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in the selexipag technology space
- See which companies are most active in crystalline compound patents
- Understand polymorph claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own API or formulation.
- Input your compound structure or technical features
- AI identifies potentially blocking polymorph and formulation patents
- Get actionable risk assessment report
High Risk Area
API Polymorph Infringement
2 Patents at Issue
Crystal Form & Use Patents
Design-Around Options
Potential alternative polymorphs
✅ Key Takeaways
Polymorph patents on sole viable crystal forms represent durable enforcement assets in pharmaceutical patent litigation.
Search related case law →Consent judgments with broad permanent injunctions can be more valuable than litigated wins — delivering certainty without appellate risk.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent Nos. 8,791,122 and 9,284,280, both covering the Form-I crystal of selexipag (the active ingredient in Uptravi®) and its pharmaceutical use.
The parties stipulated to entry of judgment, with Cipla agreeing that both patents are valid and enforceable for purposes of this action, resulting in a permanent injunction blocking Cipla’s generic selexipag for injection product until patent expiration.
This case reinforces that crystal form patents on sole commercially viable polymorphs carry significant enforceability weight and can independently sustain permanent injunctive relief, encouraging innovators to pursue and enforce polymorph patent portfolios aggressively.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case No. 1:23-cv-00389
- USPTO Patent Center — US 8,791,122 & US 9,284,280
- Cornell Legal Information Institute — 35 U.S.C. § 289 (General legal reference)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.